OmniSeq is seeking a MD/DO-licensed Molecular Pathologist, licensed to practice medicine in New York State or with the ability to obtain a NYS license. The applicant will direct a CLIA CAP and NYS state-of- the-art next generation sequencing (NGS) laboratory.
The applicant will have the opportunity to sign out multiple types of NGS assays, including both DNA-seq and RNA-seq, as well as participate in the development of future assays. Clinically, the current need is to actively participate in both genomic and immune-oncology NGS solid tumor profiling assays that support physician decision making for both targeted therapies and immunotherapies. From a translational perspective, there is significant opportunity to participate in R&D of future NGS assays that will allow for high impact publications as well as multiple speaking opportunities.
The applicant will participate in clinical sign-out as well as develop a translational biomarker program with an emphasis on both genomics and immunology. Numerous opportunities exist for collaborative research with other clinicians and basic scientists at RPCI and OmniSeq’s other research partners.
Candidates must have or be eligible for: New York State full licensure (MD/DO), American Board of Pathology Certification in Molecular Pathology or American Board of Medical Genetics and Genomics (ABMGG) and New York State Certificate of Qualification, qualifications in Oncology (molecular and cellular tumor markers).
Candidates with molecular pathology fellowship training, prior experience in molecular diagnostics, and/or experience or training in next generation sequencing for cancer testing will be given preference. Knowledge of Informatics a plus.
Experience with Laboratory Information Systems, CLIMS and informatics solutions preferred.
Candidates must be eligible to work in the U.S., as sponsorship is NOT available.
To apply, please forward your resume to Colleen Scharf, VP of Operations at email@example.com